272
Participants
Start Date
January 25, 2019
Primary Completion Date
July 20, 2021
Study Completion Date
August 30, 2023
Semorinemab
Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
Placebo
Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
[18F]GTP1
\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Empire Neurology PC; MS Center of Northeastern NY, Latham
CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille
University of Rochester; AD-CARE, Rochester
Abington Neurological Associates, Abington
Synexus Clinical Research US, Inc. - Orlando, Orlando
Miami Jewish Health Systems, Miami
Premiere Research Institute, West Palm Beach
Alzheimer?s Research and Treatment Center, Wellington
Brain Matters Research, Inc., Delray Beach
JEM Research LLC, Atlantis
Neuropsychiatric Research; Center of Southwest Florida, Fort Myers
Collier Neurologic Specialists, Naples
Bradenton Research Center, Bradenton
CHU Rennes - Hopital Pontchaillou, Rennes
New Orleans Center for Clinical Research, Knoxville
Neurology Clinic PC, Cordova
Hospital Universitario Doctor Peset, Valencia
Hospital Universitari i Politecnic La Fe, Valencia
Center for Memory and Aging, Saint Paul
Alexian Brothers Neuroscience Institute, Elk Grove Village
Rush University Medical Center - Chicago, Chicago
Southern Illinois University, School of Medicine, Springfield
Hopital des Charpennes, Villeurbanne
Chu Toulouse, Bron
Groupe Hospitalier Pitie-Salpetriere, Paris
Pharmacology Research Institute, Los Alamitos
Pacific Research Network - PRN, San Diego
Collaborative Neuroscience Network, Inc., Garden Grove
Stanford University; Stanford Clinical Cancer Ctr, Palo Alto
Summit Research Network Inc., Portland
Molecular Neuroimaging; MRI/PET, New Haven
KI Health Partners, LLC; New England Institute for Clinical Research, Stamford
Brigham and Womens Hospital; Center for Alzheimer Research & Treatment, Boston
Alzheimers Disease Center, Quincy
Advanced Memory Research Institute of NJ, Toms River
Rhode Island Mood & Memory Research Institute, East Providence
Butler Hospital; Movement Disorders Program, Providence
The Memory Clinic, Bennington
Podlaskie Centrum Psychogeriatrii, Bia?ystok
Novo-Med Zielinski i wspolnicy Sp. j., Katowice
NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Późna
Osrodek Badan Klinicznych Euromedis, Szczecin
Centrum Medyczne NeuroProtect, Warsaw
Centrum Medyczne AMED, Warsaw
NZOZ WCA, Wroc?aw
Hospital Mutua de Terrassa, Terrassa
Fundacio ACE, Barcelona
Hospital Clinic I Provincial, Barcelona
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona
Lead Sponsor
Genentech, Inc.
INDUSTRY